WATCH-PD/Konektm overlap, SWO-001 Japan / CarefoOne Apple Watch ongoing rows, (Drowy, 2020 #1223) Comparison of drug pharmacotherapy survey table, Digital PD Summary (US/EU vs Japan studies), Disease area TM strategy (Mitochondria / Neurodegeneration / POC framework / Human sample / Disease modelling), Project relevance / Candidate BM / Assay development matrix (α-Syn CSF / α-Syn PET / α-Syn Retina / lysosomal markers / CSF p65-Ub / functional mitochondrial CSF BM / NAD+ 31P MRS imaging)

study
SWO-001 / Japan (JMO-managed)	An Observational Study by Application of Wearable, Multi-Sensor Technology to Characterize Motor Function of Parkinson's Disease Patients in Japan / Elderly PD patients (1) (1, 1, 1, 1) (Apple) / Verify watch (google) / validation plan, (analytic & clinical) / correlation with datscan, genotyping / characterization / clinical validation / Ongoing
CarefoOne / Japan (JMO-managed)	Apple Watch / ongoing

(Drowy, 2020 #1223) Comparison of drug pharmacotherapy in Parkinson’s disease — Table 1

Study	Primary funders	Design	Sample	Geography	Duration	Frequency of visits	Clinical Patient population	Digital tools	Biological samples
Parkinson's Progression Markers Initiative (PPMI)	Michael J Fox Foundation	Multi-center	2000	Yes	10+ years	3-, 6-, 12-month interval	Yes	Smartwatch Smartphone application	Blood CSF Stool
Personalized Parkinson's Project (PPP)	Verily Life Sciences LLC	Single-center	650	No	2 years	Annual	Yes	Smartwatch	Blood Tissue Stool
Luxembourg Parkinson's Study	Luxembourg National Research Fund	Multi-center	1500	No	4 years	Annual	Yes	Smartwatch	Blood Tissue Saliva
WATCH-PD (US)	Biogen and Takeda	Multi-center	100	No	1- and 12-month interval	Yes	Smartwatch Smartphone application	Blood	None
University of Rochester Udall Center	National Institute of Neurological Disorders and Stroke	Multi-center	50	No	2 years	6- and 12-month interval	Yes	Smartphone application Wearable sensors	Blood

Digital PD / Summary

Study	Location	Device	Status
Digital PD	US/EU	potentially the BluKey Project of Pfizer; MPower; or Intel
WATCH-PD	US	Apple Watch + iPhone, APDM wearable sensors (https://www.apdm.com/) characterization clinical validation correlation with DaTscan	Ongoing https://watchddstudy.org/
SWO-001	Japan (JMO-managed)	Verily watch (google) / validation plan, (analytic & clinical) / correlation with datscan, genotyping / characterization / clinical validation	Ongoing
CarefoOne	Japan (JMO-managed)	Apple Watch	ongoing

Disease area TM strategy

area
Mitochondria	Patient stratification strategy in lpd
Neurodegeneration	Parkin-PD 가 가가 좋겠네요, GBA-PD/ Atalas의 다 가 가 환자 가 가게 가 가 PD/ neurodegenerative model in lpd 가 발다.
POC decision making framework	MDS-UPDRS analysis
human sample	Niigata univ Brain sample, Parkin-PD UK brain banks (GIBA, Parkin-PD) MJFF CSF sample (GBA, Parkin-PD)
Disease modelling	Patient segmentation with NLRP3

Gap pathway	Project relevance	Candidate BM	BM discovery (identification)	Assay development
α-syn	SNCA ASO SNCA HDO GBA activator, GBA GT NLRP3i	p-aSyn (CSF)	Identified in iPD patients (brain and CSF)	BTV achieved (FY20 Q3)
		Oligomeric aSyn (CSF)	Identified in iPD patients (brain and CSF)	RT-Quic PS started (seeding-based assay) Non seeding-based assay to be proposed (Waseda univ collaboration)
		aSyn PET α-Syn Retina	Identified in iPD patients (brain) Validation in retina circulates with brain α-Syn in sPD	Animal model needs to be developed
lysosome	GBA activator, GBA GT	Lysosomal autophagy markers and general lysosomal markers	- Identified in GBA-PD patients brain plan: - Validation in GBA-PD patients CSF from NCNP in 2021 - Assessment in GBA animal model (ARNJ)	Cathepsin activity assay started (BFA by FY21 Q3) May add other lysosomal assay depending on animal model findings.
mitochondria	Parkin GT cGASi	MC1 PET	- Identified in Parkin-PD patients (fibroblast) and animal model Plan: - Validation in Parkin-PD patient brain (clinical PET study)	Already established
		CSF p65-Ub (mitophagy marker)	- Identified in Parkin-PD patients (brain CSF Plan) - Validation in Parkin-PD patients CSF (now contacting MJFF)	assay development started (BFA by FY21 Q1)
		Functional mitochondrial CSF BM	- Some molecular markers (membrane potential, ATP) change in Parkin-PD patients (fibroblast). Plan: - Will select candidate molecular markers (Niigata univ collaboration) - Validate in Parkin-PD patient brain (Niigata univ collaboration) - Validate in Parkin-PD patient CSF (MJFF univ collaboration)	To be developed Fill will start in 2021 May
		Functional mitochondrial imaging	Brain imaging tools (eg NAD+, 31P MRS) are available but not tested in PD Plan
inflammation	cGASi NLRP3i

Uncertain Spans

location	transcription	uncertainty
Disease area / Neurodegeneration cell	Parkin-PD 가 가가 좋겠네요, GBA-PD/ Atalas의 다 가 가 환자 가 가게 가 가 PD/ neurodegenerative model in lpd 가 발다.	mixed Korean / English narrative with OCR artefacts; preserved verbatim.